Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2014 (2014), Article ID 578741, 14 pages
http://dx.doi.org/10.1155/2014/578741
Research Article

Alpha/Beta T-Cell Depleted Grafts as an Immunological Booster to Treat Graft Failure after Hematopoietic Stem Cell Transplantation with HLA-Matched Related and Unrelated Donors

1Department of Oncology and Pathology, Karolinska Institutet, 141 86 Stockholm, Sweden
2Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, 141 86 Stockholm, Sweden
3Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, 141 86 Stockholm, Sweden

Received 5 May 2014; Revised 4 September 2014; Accepted 4 September 2014; Published 13 October 2014

Academic Editor: David E. Gilham

Copyright © 2014 E. Rådestad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Remberger, M. Ackefors, S. Berglund et al., “Improved survival after allogeneic hematopoietic stem cell transplantation in recent years: a single-center study,” Biology of Blood and Marrow Transplantation, vol. 17, no. 11, pp. 1688–1697, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. O. Ringdén, M. Okas, M. Uhlin, M. Uzunel, M. Remberger, and J. Mattsson, “Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor,” Bone Marrow Transplantation, vol. 42, no. 10, pp. 643–648, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. O. Ringdén, “Bone marrow transplantation using unrelated donors for haematological malignancies,” Medical Oncology, vol. 14, no. 1, pp. 11–22, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. M. G. Kiehl, L. Kraut, R. Schwerdtfeger et al., “Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission,” Journal of Clinical Oncology, vol. 22, no. 14, pp. 2816–2825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Kanakry, Y. L. Kasamon, C. D. Gocke et al., “Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma,” Biology of Blood and Marrow Transplantation, vol. 19, no. 4, pp. 602–606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Uhlin, H. Wikell, M. Sundin et al., “Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation,” Haematologica, vol. 99, no. 2, pp. 346–352, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Mattsson, O. Ringdén, and R. Storb, “Graft failure after allogeneic hematopoietic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 14, no. 1, pp. 165–170, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. E. Bernardo, L. M. Ball, A. M. Cometa et al., “Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation,” Bone Marrow Transplantation, vol. 46, no. 2, pp. 200–207, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Horowitz, R. P. Gale, P. M. Sondel et al., “Graft-versus-leukemia reactions after bone marrow transplantation,” Blood, vol. 75, no. 3, pp. 555–562, 1990. View at Google Scholar · View at Scopus
  10. R. Nakamura, E. Bahceci, E. J. Read et al., “Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back,” British Journal of Haematology, vol. 115, no. 1, pp. 95–104, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-J. Kolb, “Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties,” Vox Sanguinis, vol. 74, supplement 2, pp. 321–329, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. D. Sairafi, M. Remberger, M. Uhlin, P. Ljungman, O. Ringdén, and J. Mattsson, “Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions,” Biology of Blood and Marrow Transplantation, vol. 16, no. 12, pp. 1728–1737, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Remberger, O. Ringdén, P. Ljungman et al., “Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation,” Bone Marrow Transplantation, vol. 22, no. 1, pp. 73–78, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Olivero, G. Novakovitch, P. Ladaique et al., “T-cell depletion of allogeneic bone marrow grafts: enrichment of mononuclear cells using the COBE Spectra cell processor, followed by immunoselection of CD34+ cells,” Cytotherapy, vol. 1, no. 6, pp. 469–477, 1999. View at Google Scholar · View at Scopus
  15. P. V. O'Donnell, B. Myers, J. Edwards, K. Loper, P. Rhubart, and S. J. Noga, “CD34 selection using three immunoselection devices: comparison of T-cell depleted allografts,” Cytotherapy, vol. 3, no. 6, pp. 483–488, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Larocca, G. Piaggio, M. Podestà et al., “A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation,” Haematologica, vol. 91, no. 7, pp. 935–940, 2006. View at Google Scholar · View at Scopus
  17. A. Stasia, A. Ghiso, F. Galaverna et al., “CD34 selected cells for the treatment of poor graft function after allogeneic stem cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 20, no. 9, pp. 1440–1443, 2014. View at Publisher · View at Google Scholar
  18. R. Chakraverty, S. Robinson, K. Peggs et al., “Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation,” Bone Marrow Transplantation, vol. 28, no. 9, pp. 827–834, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Lilleri, G. Gerna, C. Fornara et al., “Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation,” Journal of Infectious Diseases, vol. 199, no. 6, pp. 829–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. W. A. Bethge, C. Faul, M. Bornhäuser et al., “Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update,” Blood Cells, Molecules, and Diseases, vol. 40, no. 1, pp. 13–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Schumm, P. Lang, W. Bethge et al., “Depletion of T-cell receptor alpha/beta and CD19 positive cells from apheresis products with the CliniMACS device,” Cytotherapy, vol. 15, no. 10, pp. 1253–1258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Vantourout and A. Hayday, “Six-of-the-best: unique contributions of γδ T cells to immunology,” Nature Reviews Immunology, vol. 13, no. 2, pp. 88–100, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Knight, A. J. Madrigal, S. Grace et al., “The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation,” Blood, vol. 116, no. 12, pp. 2164–2172, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Halary, V. Pitard, D. Dlubek et al., “Shared reactivity of Vδ2neg γδ T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells,” Journal of Experimental Medicine, vol. 201, no. 10, pp. 1567–1578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Pitard, D. Roumanes, X. Lafarge et al., “Long-term expansion of effector/memory Vδ2γδ T cells is a specific blood signature of CMV infection,” Blood, vol. 112, no. 4, pp. 1317–1324, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. M. van Dongen, A. W. Langerak, M. Brüggemann et al., “Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936,” Leukemia, vol. 17, no. 12, pp. 2257–2317, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Q. Gomes, D. S. Martins, and B. Silva-Santos, “Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application,” Cancer Research, vol. 70, no. 24, pp. 10024–10027, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. K. T. Godder, P. J. Henslee-Downey, J. Mehta et al., “Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation,” Bone Marrow Transplantation, vol. 39, no. 12, pp. 751–757, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. F. Locatelli, A. Bauquet, G. Palumbo, F. Moretta, and A. Bertaina, “Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation,” Immunology Letters, vol. 155, no. 1-2, pp. 21–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Mattsson, M. Uzunel, L. Tammik, J. Aschan, and O. Ringdén, “Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation,” Leukemia, vol. 15, no. 12, pp. 1976–1985, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Uhlin, E. Sandalova, M. G. Masucci, and V. Levitsky, “Help signals provided by lymphokines modulate the activation and apoptotic programs induced by partially agonistic peptides in specific cytotoxic T lymphocytes,” European Journal of Immunology, vol. 35, no. 10, pp. 2929–2939, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. H.-J. Kolb, A. Schattenberg, J. M. Goldman et al., “Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients,” Blood, vol. 86, no. 5, pp. 2041–2050, 1995. View at Google Scholar · View at Scopus
  33. M. D. de Pasquale, A. Mastronuzzi, R. de Vito et al., “Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation,” Pediatrics, vol. 129, no. 1, pp. e189–e194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. J. L. M. Ferrara and P. Reddy, “Pathophysiology of graft-versus-host disease,” Seminars in Hematology, vol. 43, no. 1, pp. 3–10, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. C. Booth, J.-A. Ribeil, F. Audat et al., “CD34+ stem cell top-ups without conditioning after initial haematopoietic stem cell transplantation for correction of incomplete haematopoietic and immunological recovery in severe congenital immunodeficiencies,” British Journal of Haematology, vol. 135, no. 4, pp. 533–537, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Chaleff, M. Otto, R. C. Barfield et al., “A large-scale method for the selective depletion of αβ T lymphocytes from PBSC for allogeneic transplantation,” Cytotherapy, vol. 9, no. 8, pp. 746–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Gogoi and S. V. Chiplunkar, “Targeting gamma delta T cells for cancer immunotherapy: bench to bedside,” Indian Journal of Medical Research, vol. 138, pp. 755–761, 2013. View at Google Scholar · View at Scopus
  38. H. Kobayashi, Y. Tanaka, J. Yagi, N. Minato, and K. Tanabe, “Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma,” Cancer Immunology, Immunotherapy, vol. 60, no. 8, pp. 1075–1084, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. W. Scheper, S. Van Dorp, S. Kersting et al., “γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia,” Leukemia, vol. 27, no. 6, pp. 1328–1338, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Hua, N. Kang, Y.-A. Gao, L.-X. Cui, D.-N. Ba, and W. He, “Potential regulatory role of in vitro-expanded Vδ1 T cells from human peripheral blood,” Immunologic Research, vol. 56, no. 1, pp. 172–180, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. J. Déchanet, P. Merville, A. Lim et al., “Implication of γδ T cells in the human immune response to cytomegalovirus,” Journal of Clinical Investigation, vol. 103, no. 10, pp. 1437–1449, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. M. E. Cela, M. S. Holladay, C. M. Rooney et al., “γδ T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors,” Bone Marrow Transplantation, vol. 17, no. 2, pp. 243–247, 1996. View at Google Scholar · View at Scopus
  43. X. Lafarge, P. Merville, M.-C. Cazin et al., “Cytomegalovirus infection in transplant recipients resolves when circulating γδ T lymphocytes expand, suggesting a protective antiviral role,” Journal of Infectious Diseases, vol. 184, no. 5, pp. 533–541, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Hirokawa, T. Horiuchi, Y. Kawabata, A. Kitabayashi, and A. B. Miura, “Reconstitution of γδ T cell repertoire diversity after human allogeneic hematopoietic cell transplantation and the role of peripheral expansion of mature T cell population in the graft,” Bone Marrow Transplantation, vol. 26, no. 2, pp. 177–185, 2000. View at Publisher · View at Google Scholar · View at Scopus
  45. M. A. Slatter, A. Bhattacharya, M. Abinun, T. J. Flood, A. J. Cant, and A. R. Gennery, “Outcome of boost haemopoietic stem cell transplant for decresed donor chimerism or graft dysfunction in primary immunodeficiency,” Bone Marrow Transplantation, vol. 35, no. 7, pp. 683–689, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. B. R. Blazar, W. J. Murphy, and M. Abedi, “Advances in graft-versus-host disease biology and therapy,” Nature Reviews Immunology, vol. 12, no. 6, pp. 443–458, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Ruggeri, F. Aversa, M. F. Martelli, and A. Velardi, “Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self,” Immunological Reviews, vol. 214, no. 1, pp. 202–218, 2006. View at Publisher · View at Google Scholar · View at Scopus